Open Journal of Blood Diseases

Volume 11, Issue 1 (March 2021)

ISSN Print: 2164-3180   ISSN Online: 2164-3199

Google-based Impact Factor: 0.46  Citations  

Progress in the Treatment of Hematological Diseases with Rituximab

HTML  XML Download Download as PDF (Size: 299KB)  PP. 6-14  
DOI: 10.4236/ojbd.2021.111002    757 Downloads   1,951 Views  

ABSTRACT

Rituximab is a mouse and human chimeric CD20 (anti-B cell) specific monoclonal antibody that has been approved by the U.S. Food and Drug Administration for the treatment of lymphoma. The expression of CD20 antigen is expressed in the whole ontogeny of B cells, starting from the premature B cells in bone marrow to the differentiation of plasma cells in secondary lymphoid tissues. The wide distribution of CD20 molecules allows rituximab to eliminate a large number of B cells. Rituximab is the core drug for the treatment of hematological diseases, often combined with drugs as a first-line treatment. Long-term hormone therapy often results in serious adverse reactions, and new therapies, which can avoid widespread immunotoxicity, have great potential for treating diseases of the blood system.

Share and Cite:

Fu, X. , Lin, L. , Yao, H. , Huang, L. , Meng, C. , Wang, S. , Liu, D. , Guo, L. and Duan, M. (2021) Progress in the Treatment of Hematological Diseases with Rituximab. Open Journal of Blood Diseases, 11, 6-14. doi: 10.4236/ojbd.2021.111002.

Cited by

No relevant information.

Copyright © 2025 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.